Progress towards precision medicine for lupus

The role of genetic biomarkers

Juan Manuel Anaya, Kelly J. Leon, Manuel Rojas, Yhojan Rodriguez, Yovana Pacheco, Yeny Acosta-Ampudia, Diana M. Monsalve, Carolina Ramirez-Santana

Resultado de la investigación: Contribución a RevistaArtículo

2 Citas (Scopus)

Resumen

El lupus eritematoso sistémico (LES) es la enfermedad autoinmune sistémica (EA) prototípica. La medicina de precisión les da a los médicos y a la sociedad acceso a la información necesaria para crear programas personalizados para predecir, prevenir y tratar el LES. Aunque se han descrito varios biomarcadores para el LES, la actual expansión del conocimiento sobre la genética del lupus hace posible la implementación de biomarcadores genéticos. Aquí se ofrece una descripción completa de los biomarcadores genéticos relevantes para el LES desde la perspectiva de la medicina de precisión. Se deben crear cohortes nacionales de inicio y poner en práctica la implementación de programas de traslación para el control de enfermedades de Alzheimer como el LES. Los factores que predicen el desarrollo de estas afecciones deben ser examinados a nivel de la población para establecer medidas preventivas en los individuos en situación de riesgo para los que la atención sanitaria debe ser personalizada/precisa y participativa. La implementación de tal programa permitirá el descubrimiento de nuevos mecanismos y una nueva taxonomía de las enfermedades de Alzheimer. El modelo traslacional también debe incluir programas de educación y capacitación junto con sistemas digitales de vigilancia participativa. El enfoque único de la atención médica para el tratamiento de los pacientes será reemplazado por un enfoque de medicina personalizado y de precisión que se centra en las personas y en cada miembro de la familia.
Idioma originalEnglish (US)
Páginas (desde-hasta)119-135
Número de páginas17
PublicaciónExpert Review of Precision Medicine and Drug Development
Volumen3
N.º2
DOI
EstadoPublished - mar 15 2018

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Molecular Medicine
  • Genetics

Citar esto

Anaya, Juan Manuel ; Leon, Kelly J. ; Rojas, Manuel ; Rodriguez, Yhojan ; Pacheco, Yovana ; Acosta-Ampudia, Yeny ; Monsalve, Diana M. ; Ramirez-Santana, Carolina. / Progress towards precision medicine for lupus : The role of genetic biomarkers. En: Expert Review of Precision Medicine and Drug Development. 2018 ; Vol. 3, N.º 2. pp. 119-135.
@article{248aa0f9e3734bd5961c4097d247c942,
title = "Progress towards precision medicine for lupus: The role of genetic biomarkers",
abstract = "Systemic lupus erythematosus (SLE) is the prototypical systemic autoimmune disease (AD). Precision medicine gives clinicians and society access to the information needed to create individually tailored programs to predict, prevent, and treat SLE. Although several biomarkers have been described for SLE, current expansion of knowledge on lupus genetics makes the implementation of genetic biomarkers possible. Herein, a comprehensive description of relevant SLE genetic biomarkers from the precision medicine perspective is offered. National inception cohorts should be created and the implementation of translational programs for the control of ADs such as SLE should be put into practice. Factors that are predictive of developing these conditions should be examined at the population level in order to establish preventive measures in at-risk individuals for whom healthcare should be personalized/precise and participatory. The implementation of such a program will allow the discovery of new mechanisms and a new taxonomy of ADs. The translational model should also involve educational and training programs together with digital participatory surveillance systems. Healthcare’s one-size-fits-all approach to treating patients will be replaced with a personalized/precision approach to medicine that focuses on individuals and each family member.",
author = "Anaya, {Juan Manuel} and Leon, {Kelly J.} and Manuel Rojas and Yhojan Rodriguez and Yovana Pacheco and Yeny Acosta-Ampudia and Monsalve, {Diana M.} and Carolina Ramirez-Santana",
year = "2018",
month = "3",
day = "15",
doi = "10.1080/23808993.2018.1448266",
language = "English (US)",
volume = "3",
pages = "119--135",
journal = "Expert Review of Precision Medicine and Drug Development",
issn = "2380-8993",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

Progress towards precision medicine for lupus : The role of genetic biomarkers. / Anaya, Juan Manuel; Leon, Kelly J.; Rojas, Manuel; Rodriguez, Yhojan; Pacheco, Yovana; Acosta-Ampudia, Yeny; Monsalve, Diana M.; Ramirez-Santana, Carolina.

En: Expert Review of Precision Medicine and Drug Development, Vol. 3, N.º 2, 15.03.2018, p. 119-135.

Resultado de la investigación: Contribución a RevistaArtículo

TY - JOUR

T1 - Progress towards precision medicine for lupus

T2 - The role of genetic biomarkers

AU - Anaya, Juan Manuel

AU - Leon, Kelly J.

AU - Rojas, Manuel

AU - Rodriguez, Yhojan

AU - Pacheco, Yovana

AU - Acosta-Ampudia, Yeny

AU - Monsalve, Diana M.

AU - Ramirez-Santana, Carolina

PY - 2018/3/15

Y1 - 2018/3/15

N2 - Systemic lupus erythematosus (SLE) is the prototypical systemic autoimmune disease (AD). Precision medicine gives clinicians and society access to the information needed to create individually tailored programs to predict, prevent, and treat SLE. Although several biomarkers have been described for SLE, current expansion of knowledge on lupus genetics makes the implementation of genetic biomarkers possible. Herein, a comprehensive description of relevant SLE genetic biomarkers from the precision medicine perspective is offered. National inception cohorts should be created and the implementation of translational programs for the control of ADs such as SLE should be put into practice. Factors that are predictive of developing these conditions should be examined at the population level in order to establish preventive measures in at-risk individuals for whom healthcare should be personalized/precise and participatory. The implementation of such a program will allow the discovery of new mechanisms and a new taxonomy of ADs. The translational model should also involve educational and training programs together with digital participatory surveillance systems. Healthcare’s one-size-fits-all approach to treating patients will be replaced with a personalized/precision approach to medicine that focuses on individuals and each family member.

AB - Systemic lupus erythematosus (SLE) is the prototypical systemic autoimmune disease (AD). Precision medicine gives clinicians and society access to the information needed to create individually tailored programs to predict, prevent, and treat SLE. Although several biomarkers have been described for SLE, current expansion of knowledge on lupus genetics makes the implementation of genetic biomarkers possible. Herein, a comprehensive description of relevant SLE genetic biomarkers from the precision medicine perspective is offered. National inception cohorts should be created and the implementation of translational programs for the control of ADs such as SLE should be put into practice. Factors that are predictive of developing these conditions should be examined at the population level in order to establish preventive measures in at-risk individuals for whom healthcare should be personalized/precise and participatory. The implementation of such a program will allow the discovery of new mechanisms and a new taxonomy of ADs. The translational model should also involve educational and training programs together with digital participatory surveillance systems. Healthcare’s one-size-fits-all approach to treating patients will be replaced with a personalized/precision approach to medicine that focuses on individuals and each family member.

UR - http://www.scopus.com/inward/record.url?scp=85053369428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053369428&partnerID=8YFLogxK

U2 - 10.1080/23808993.2018.1448266

DO - 10.1080/23808993.2018.1448266

M3 - Article

VL - 3

SP - 119

EP - 135

JO - Expert Review of Precision Medicine and Drug Development

JF - Expert Review of Precision Medicine and Drug Development

SN - 2380-8993

IS - 2

ER -